2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex- 2-enone: glyoxalase I inhibitor from culture broth of Streptomyces griseosporeus; RN given refers to (3R-(1(E),3alpha,4alpha,5alpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6438556 |
| CHEMBL ID | 361592 |
| SCHEMBL ID | 11777188 |
| SCHEMBL ID | 11777173 |
| MeSH ID | M0057311 |
| Synonym |
|---|
| 2-cyclohexen-1-one, 2-(hydroxymethyl)-4r,5r,6r-trihydroxy-, 2-ester with (e)-crotonic acid |
| 2-crotonyloxymethyl-(4r,5r,6r)-4,5,6-trihydroxycyclohex-2-enone |
| glyoxalase-i inhibitor |
| 2-crotonyloxymethyl-4r,5r,6r-4,5,6-trihydroxycyclohex-2-enone |
| CHEMBL361592 |
| [(3r,4r,5r)-3,4,5-trihydroxy-6-oxocyclohexen-1-yl]methyl (e)-but-2-enoate |
| 62532-49-4 |
| 2-crotonyloxymethyl-(4r,5r,6r)-4,5,6-trihydroxycyclohex- 2-enone |
| SCHEMBL11777188 |
| SCHEMBL11777173 |
| 2-crotonyloxymethyl-(4r,5r,6r)-4,5,6-trihydroxy-2-cyclohexenone |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recombinant spores expressing tetanus toxin fragment C (TTFC) of Clostridium tetani or the B subunit of the heat-labile toxin of Escherichia coli (LTB) were used for oral dosing and shown to generate specific systemic and mucosal immune responses in a murine model." | ( Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner. Cangiano, G; Cutting, SM; De Felice, M; Duc, le H; Hong, HA; Isticato, R; Mauriello, EM; Ricca, E, 2004) | 0.32 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID251126 | Effect of COTC on GSH level in human pancreatic adenocarcinoma cell was determined at 30 ug/mL of COTC | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||